The discovery and development process for Antibody Drug Conjugates (ADCs), or immunoconjugates, is complex and poses significant challenges. Genedata Biologics supports the full ADC discovery process from antibody screening and engineering, to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g., DAR, drug distribution, homogeneity).
ADC Design, Engineering & Testing
Genedata Biologics enables the registration and tracking of large panels of ADC candidates and manages all linker and payload information (e.g., cytotoxic small molecules). By incorporating results from analytics and functional assays in one integrated platform, Genedata Biologics substantially increases throughput and efficiency in ADC discovery.
Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
Dominik Maurer, Ph.D.
VP Immunology
Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts.
Marc Van Dijk, Ph.D.
Chief Technology Officer
Immatics streamlines CGT processes with Genedata
"The Genedata platform has provided efficiency gains on many fronts, eliminated redundancies in our daily work, and decreased our overall ongoing operating costs." Sebastian Bunk, Ph.D., Senior Director TCR Bispecifics Pipeline, Immatics.
Helping MorphoSys Increase Efficiencies Across Their R&D
"Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts.” Marc Van Dijk, Ph.D., Chief Technology Officer